Christine Cotton Preservation archive
English Français

← All interviews · All research follow-ups →

REVAV AG Intervention de Christine Cotton Biostatisticienne octobre 2022

Guillaume Ageorges · YouTube · Watch ▶

📅 2022-10-31🎙️ Guillaume Ageorges (host, REVAV AG general assembly)📺 Guillaume Ageorges — YouTube channel (REVAV AG)⏱ 29 min
“The biggest cover-up of the COVID clinical trials is this: they did not measure antibodies at three months because they knew they would drop. They knew from the start — and the HAS opinion shows Pfizer was already studying a booster in December 2020.”

Key statements

  • A 22 October 2020 FDA presentation lists possible adverse-event outcomes to monitor: Guillain-Barré, encephalomyelitis, transverse myelitis, convulsions, narcolepsy, anaphylaxis, myocarditis, autoimmune disease, death, pregnancy complications, thrombocytopenia, thromboembolism, and pediatric multisystem inflammatory syndrome (PIMS). The slide subsequently disappeared from regulatory meetings. ▶ 03:42
    Sources: FDA VRBPAC meeting (22 October 2020) — adverse events of special interest slides
  • Pfizer's preclinical macaque data show neutralizing antibodies rising at 21-28 days, peaking, and dropping by day 56 — a curve visible in the FDA briefing dossier before the first authorization. Anti-N antibodies were not available so neutralizing antibodies were chosen as the immunity marker. ▶ 05:16
    Sources: Pfizer preclinical macaque study; FDA VRBPAC briefing dossier (Dec 2020)
  • In November 2020, former French health minister Philippe Douste-Blazy said publicly: "It's nice, vaccines, but let's not get carried away — protection only lasts about two months." He subsequently disappeared from media circulation. ▶ 07:01
    Sources: Douste-Blazy public interview (Nov 2020)
  • Computed against anti-nucleocapsid seroconversion — the marker that catches anyone who actually caught COVID during the trial — efficacy is about 55-56%, not 95%. ▶ 10:03
    Sources: Pfizer C4591001 court-released trial database (PHMPT / FOIA)
  • The C4591001 protocol's visit schedule has a gaping hole: between day 56 and 6 months, no antibody titre is taken. A 3-month measurement would have shown the drop — and is the single most important omission of the Pfizer trial and of every COVID vaccine trial. ▶ 13:48
    Sources: Pfizer C4591001 Protocol (immunogenicity schedule)
  • Pfizer did not measure antibodies at three months because they already knew the drop would force regulators either to refuse authorization or to announce up front that boosters would be needed — invalidating the "two doses and back to normal life" narrative. ▶ 14:39
    Sources: Pfizer C4591001 Protocol (immunogenicity schedule); HAS opinion on Comirnaty (December 2020)
  • The November 2020 Risk Management Plan lists the same gaps as the September 2022 update — pregnant or breastfeeding women, immunocompromised patients, autoimmune disease, no co-administration interaction study. Anaphylaxis was the only item removed ("known now"); everything else remained an unknown. ▶ 19:52
    Sources: Comirnaty Risk Management Plan (Nov 2020, EMA); Comirnaty Risk Management Plan (Sept 2022, EMA)
  • Direct evidence of GCP fraud comes from Brook Jackson (Ventavia, US), Augusto Roux (Argentina — multiple serious events not in the clinical report), and Maddie de Garay (US adolescent trial). Tolerance evaluation in the Pfizer trial is therefore false at face value. ▶ 22:47
    Sources: Brook Jackson — Ventavia whistleblower BMJ report (Thacker, 2021); Augusto Roux medical file; Maddie de Garay testimony to Sen. Ron Johnson
  • Per a paper by the head of French CRPV (Joëlle Micallef), only 1-10% of adverse events are reported. France's ANSM database holds about 182,000 Pfizer-vaccine cases, of which 25% are serious — extrapolated to true incidence, the figures are an order of magnitude larger. ▶ 25:21
    Sources: ANSM pharmacovigilance reports; Micallef et al. — paper on adverse-event under-reporting
  • France's regional pharmacovigilance centres (CRPV) appear to systematically push back imputability — demanding extra exams and dragging out cases — rather than declaring a vaccine link. Cotton works closely with REACT C19 patients (small-fiber neuropathy, tinnitus, neurological symptoms) who are largely abandoned by the medical system. ▶ 28:14
    Sources: ANSM pharmacovigilance reports; REACT C19 patient association — testimonies

Documents cited

  • FDA VRBPAC meeting (22 October 2020) — adverse events of special interest slides — FDA YouTube channel / VRBPAC public materials
  • Pfizer preclinical macaque study (incl. neutralizing antibody curves) — FDA briefing document, Dec 2020 VRBPAC
  • Pfizer C4591001 Protocol (immunogenicity schedule) — NEJM supplementary materials
  • Pfizer C4591001 court-released trial database — PHMPT / FOIA disclosures (phmpt.org)
  • Comirnaty Risk Management Plan (Nov 2020 & Sept 2022, EMA) — EMA EPAR archive
  • HAS opinion on Comirnaty (December 2020) — has-sante.fr archive
  • Brook Jackson — Ventavia whistleblower BMJ report — BMJ 2021;375:n2635 (Thacker)
  • ANSM pharmacovigilance reports — ansm.sante.fr
  • Micallef et al. — paper on adverse-event under-reporting (1-10% reported) — French pharmacovigilance literature

Research follow-ups

All research follow-ups →